|Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping|
DR Borger, KK Tanabe, KC Fan, HU Lopez, VR Fantin, KS Straley, ...
The oncologist 17 (1), 72, 2012
|Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice|
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ...
Annals of Oncology 22 (12), 2616-2624, 2011
|Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine|
D Dias‐Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, ...
EMBO molecular medicine 2 (5), 146-158, 2010
|RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer|
MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ...
Nature communications 6 (1), 1-10, 2015
|Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non–small-cell lung cancer|
LV Sequist, S Gettinger, NN Senzer, RG Martins, PA Jšnne, R Lilenbaum, ...
Journal of clinical oncology 28 (33), 4953, 2010
|BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications|
D Dias-Santagata, Q Lam, K Vernovsky, N Vena, JK Lennerz, DR Borger, ...
PloS one 6 (3), e17948, 2011
|Phase 1/2 study of everolimus in advanced hepatocellular carcinoma|
AX Zhu, TA Abrams, R Miksad, LS Blaszkowsky, JA Meyerhardt, H Zheng, ...
Cancer 117 (22), 5094-5102, 2011
|A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non–small-cell lung cancer|
Z Su, D Dias-Santagata, MK Duke, K Hutchinson, YL Lin, DR Borger, ...
The Journal of Molecular Diagnostics 13 (1), 74-84, 2011
|Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas|
H Wakimoto, S Tanaka, WT Curry, F Loebel, D Zhao, K Tateishi, J Chen, ...
Clinical cancer research 20 (11), 2898-2909, 2014
|Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer|
EL Kwak, LG Ahronian, G Siravegna, B Mussolin, DR Borger, JT Godfrey, ...
Cancer discovery 5 (12), 1271-1281, 2015
|Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response|
AT Fathi, H Sadrzadeh, DR Borger, KK Ballen, PC Amrein, EC Attar, ...
Blood, The Journal of the American Society of Hematology 120 (23), 4649-4652, 2012
|EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas|
RJH Ryan, M Nitta, D Borger, LR Zukerberg, JA Ferry, NL Harris, ...
PloS one 6 (12), e28585, 2011
|Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma|
DR Borger, L Goyal, T Yau, RT Poon, M Ancukiewicz, V Deshpande, ...
Clinical Cancer Research 20 (7), 1884-1890, 2014
|Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping|
RS Heist, LV Sequist, D Borger, JF Gainor, RS Arellano, LP Le, ...
Journal of Thoracic Oncology 11 (8), 1242-1245, 2016
|Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets|
AX Zhu, DR Borger, Y Kim, D Cosgrove, A Ejaz, S Alexandrescu, ...
Annals of surgical oncology 21 (12), 3827-3834, 2014
|Activation of PI3K signaling in Merkel cell carcinoma|
V Nardi, Y Song, JA Santamaria-Barria, AK Cosper, Q Lam, AC Faber, ...
Clinical Cancer Research 18 (5), 1227-1236, 2012
|Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment|
V Nardi, PM Sadow, D Juric, D Zhao, AK Cosper, K Bergethon, ...
Clinical cancer research 19 (2), 480-490, 2013
|Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma|
L Goyal, A Govindan, RA Sheth, V Nardi, LS Blaszkowsky, JE Faris, ...
The oncologist 20 (9), 1019, 2015
|A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal†…|
TS Hong, DP Ryan, DR Borger, LS Blaszkowsky, BY Yeap, ...
International Journal of Radiation Oncology* Biology* Physics 89 (4), 830-838, 2014
|Induction of heme oxygenase-1 (HSP32) mRNA in skeletal muscle following contractions|
DA Essig, DR Borger, DA Jackson
American Journal of Physiology-Cell Physiology 272 (1), C59-C67, 1997